PMID

Data

Article Title

Organization

Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells.

University Of Tennessee Health Science Center

Discovery of ONO-7300243 from a Novel Class of Lysophosphatidic Acid Receptor 1 Antagonists: From Hit to Lead.

Ono Pharmaceutical

Discovery of novel S1P2 antagonists. Part 1: discovery of 1,3-bis(aryloxy)benzene derivatives.

Ono Pharmaceutical

Design and synthesis of sulfamoyl benzoic acid analogues with subnanomolar agonist activity specific to the LPA2 receptor.

The University Of Tennessee Health Science Center

Phosphorothioate analogs of sn-2 radyl lysophosphatidic acid (LPA): metabolically stabilized LPA receptor agonists.

The University Of Utah

Selective non-lipid modulator of LPA5 activity in human platelets.

Sanofi-Aventis Deutschland

Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents.

Amgen

Synthesis and SAR studies of a novel class of S1P1 receptor antagonists.

Sankyo

Structure-based drug design identifies novel LPA3 antagonists.

The University Of Memphis

Identification of non-lipid LPA3 antagonists by virtual screening.

The University Of Memphis

Phosphonothioate and fluoromethylene phosphonate analogues of cyclic phosphatidic acid: Novel antagonists of lysophosphatidic acid receptors.

The University Of Utah

Identification of Darmstoff analogs as selective agonists and antagonists of lysophosphatidic acid receptors.

University Of Tennessee Health Science Center

Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands.

University Of Tennessee Health Science Center

Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin.

University Of Tennessee Health Science Center

Selecting against S1P3 enhances the acute cardiovascular tolerability of 3-(N-benzyl)aminopropylphosphonic acid S1P receptor agonists.

Merck Research Laboratories

Synthesis and biological evaluation of phosphonic and thiophosphoric acid derivatives of lysophosphatidic acid.

Oxford University

Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry.

X-Chem

A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA

Universidad Complutense De Madrid